Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Haleon PLC ( (GB:HLN) ) has issued an announcement.
Haleon PLC has announced the purchase and cancellation of 815,673 ordinary shares as part of its share buyback programme initiated in March 2025. This transaction impacts the company’s share capital, reducing the number of shares with voting rights, which may influence shareholder notifications under regulatory guidelines.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s stock demonstrates a strong financial foundation and promising growth in emerging markets, balanced by valuation concerns and macroeconomic challenges. The company’s strategic initiatives and innovation are positive, but careful attention to debt and external risks is necessary.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across six major categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 27,560,496
Technical Sentiment Signal: Buy
Current Market Cap: £36.46B
See more insights into HLN stock on TipRanks’ Stock Analysis page.